(Q45919628)

17 December 2017

title

Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice. (English)

1 reference

17 December 2017

1 reference

1 reference

Bonaventura Clotet Sala

7

object named as

Bonaventura Clotet

1 reference

17 December 2017

José Ramón Santos

1

1 reference

17 December 2017

José Moltó

2

1 reference

17 December 2017

Josep Maria Llibre

3

1 reference

17 December 2017

Nuria Pérez

4

1 reference

17 December 2017

Capitán

5

1 reference

17 December 2017

Cristina Miranda

6

1 reference

17 December 2017

publication date

1 May 2009

1 reference

17 December 2017

published in

HIV Clinical Trials

1 reference

17 December 2017

volume

10

1 reference

17 December 2017

issue

3

1 reference

17 December 2017

page(s)

129-134

1 reference

17 December 2017

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

cites work

1 reference

https://api.crossref.org/works/10.1310%2FHCT1003-129

Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1003-129

Pharmacokinetic enhancement of protease inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1003-129

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1003-129

Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1003-129

Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1003-129

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1003-129

Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1003-129

Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1003-129

21 January 2018

Identifiers

DOI

10.1310/HCT1003-129

1 reference

17 December 2017

1 reference

17 December 2017